+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Probi AB (PROB) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 50 Pages
  • October 2024
  • GlobalData
  • ID: 1322623
Probi AB (PROB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Probi AB (Probi), a subsidiary of Symrise AG, is a biotechnology company that develops, produces and markets probiotics. The company offers licenses for its technology and sells finished products in bulk. It focuses on products for the improvement of gastrointestinal health and immune system. Probi offers an array of probiotic products in various forms such as powders, capsules, tablets, and foods. The company sells it products under the brand name Probi. Its customers primarily consist of health, pharmaceutical, and food companies. The company’s products are used in various applications including dietary supplements and food and beverages. The company has an operational presence in Sweden, Europe, North America, and Asia Pacific. Probi is headquartered in Lund, Sweden.

Probi AB Key Recent Developments

  • Aug 14, 2024: New Study Shows Probi Strain Supports and Improves Cognitive Performance
  • Jul 16, 2024: Q2 2024: Significant Progress on Strategic Initiatives
  • Jun 27, 2024: Probi Strengthens the Gut-Brain Offering with New Study in Older Adults
  • May 07, 2024: Probi´s Annual General Meeting 2024

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Probi AB - Key Facts
  • Probi AB - Key Employees
  • Probi AB - Key Employee Biographies
  • Probi AB - Major Products and Services
  • Probi AB - History
  • Probi AB - Company Statement
  • Probi AB - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Probi AB - Business Description
  • Geographical Segment: APAC
  • Performance
  • Geographical Segment: EMEA
  • Performance
  • Geographical Segment: The Americas
  • Performance
  • R&D Overview
  • Probi AB - Corporate Strategy
  • Probi AB - SWOT Analysis
  • SWOT Analysis - Overview
  • Probi AB - Strengths
  • Probi AB - Weaknesses
  • Probi AB - Opportunities
  • Probi AB - Threats
  • Probi AB - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Probi AB, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Probi AB, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 14, 2024: New Study Shows Probi Strain Supports and Improves Cognitive Performance
  • Jul 16, 2024: Q2 2024: Significant Progress on Strategic Initiatives
  • Jun 27, 2024: Probi Strengthens the Gut-Brain Offering with New Study in Older Adults
  • May 07, 2024: Probi´s Annual General Meeting 2024
  • Mar 14, 2024: Probi strengthens its brand position and expands in the Nordics
  • Oct 24, 2023: Q3 2023: New strategic focus and improved sales trend
  • Oct 20, 2023: Probi Appoints new CFO
  • Jul 27, 2023: New Clinical Study Shows Clear Benefits of Probi’s Probiotics for Metabolic Health
  • May 04, 2023: Probi´s Annual General Meeting 2023
  • Apr 26, 2023: Q1 2023: Positive One-off Effects Contributed to Growth
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Probi AB, Key Facts
  • Probi AB, Key Employees
  • Probi AB, Key Employee Biographies
  • Probi AB, Major Products and Services
  • Probi AB, History
  • Probi AB, Subsidiaries
  • Probi AB, Key Competitors
  • Probi AB, Ratios based on current share price
  • Probi AB, Annual Ratios
  • Probi AB, Interim Ratios
  • Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Probi AB, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Probi AB, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Probi AB, Performance Chart (2019 - 2023)
  • Probi AB, Ratio Charts
  • Probi AB, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Probi AB, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Yakult Honsha Co Ltd
  • Meda AB
  • Lallemand Inc
  • Camurus AB
  • DuPont Nutrition Biosciences ApS
  • Danone SA
  • Chr. Hansen Holding AS